Johnson & Johnson (JNJ)
Is J&J's MedTech Segment Set for Another Quarter of Growth?
J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal
Douglas Lane & Associates, LLC disclosed a purchase of 34,948 shares of Johnson & Johnson (JNJ -0.24%) in an SEC filing on Friday, representing an estimated $6 million transaction based on average prices during the third quarter.
Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its oral immunology drug icotrokinra and blockbuster potential of rusfertide for polycythemia vera, both with strong partnership structures. A JNJ acquisition could save milestone payments, secure future royalties, and add derisked, late-stage assets to JNJ's portfolio, supporting long-term growth.
RTW Investments' Rod Wong: Expect more deals in biotech space
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the sector, and much more.
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced
Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. Despite solid recent earnings and raised guidance, JNJ faces headwinds from potential tariffs, drug price pressures, and declining Stelara sales. Management projects strong oncology growth, but analyst consensus remains cautious, forecasting more modest earnings growth than company targets.
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.
Goldman Sachs expects another quarter of outperformance from J&J in Q3
Johnson & Johnson (NYSE:JNJ)'s strong year-to-date performance is likely to continue when the healthcare giant reports third quarter earnings on October 14, according to analysts at Goldman Sachs. The firm wrote in a note to clients that the stock's 31% gain this year, which is more than double the S&P 500's 14% rise, reflects “impressive execution across the Innovative Medicines segment,” which has driven sales and earnings estimates higher relative to peers.
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable
A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc products cause cancer.
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensured steady Q3 momentum.
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $188.64, moving +1.43% from the previous trading session.
